Save on Calquence with Coupons, Discounts & Savings Programs

Calquence is the brand name for acalabrutinib and is available as an oral tablet.

Calquence is available as a 100 mg oral tablet.

Calquence is a kinas inhibitor that is used to treat:

• Mantle cell lymphoma (MCL)
• Chronic lymphocytic leukemia (CLL)
• Small lymphocytic lymphoma (SLL)

Calquence is a specific type of kinase inhibitor called a Bruton tyrosine kinase (BTK) inhibitor. BTK is a protein that helps MCL, CLL, and SLL cancer cells grow uncontrollably and survive. By targeting and blocking BTK, it stops cancer cell growth.

The typical starting dose of Calquence is 100 mg taken by mouth twice a day (about 12 hours apart).

• Your dose might be different if you experience certain side effects. It might also differ if you’re taking certain medications that might interact with Calquence

Calquence is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you.

Common side effects of Calquence:

• Anemia (low red blood cells)
• Low white blood cells
• Low platelets
• Respiratory tract infection
• Headache
• Diarrhea
• Muscle and joint pain
• Tiredness
• Rash
• Nausea
• Bruising
• Bleeding

Serious side effects are rare with Calquence. Contact your healthcare provider immediately if you experience any of the following.

• Serious infections: body aches, chills, fever, headache, new cough, sore throat, feeling tired
• Serious bleeding: bleeding or bruising that doesn’t stop or go away; large amount of bleeding; throwing up blood; blood in the urine; bloody or black, tarry stool
• Heart rhythm problems: fast heartbeat, chest pain, fainting, dizziness, shortness of breath

The following medications may interact with Calquence:

• Strong CYP3A Inhibitors: Avoid co-administration with Calquence
• Moderate CYP3A Inhibitors: Reduce the dosage of Calquence
• Strong CYP3A Inducers: Avoid co-administration with Calquence. If co-administration is unavoidable, increase the dosage of Calquence

AstraZeneca

Calquence may harm your unborn baby and cause problems during childbirth (dystocia). If you are able to become pregnant, your healthcare provider may do a pregnancy test before you start treatment with Calquence. Females who are able to become pregnant should use effective birth control (contraception) during treatment with Calquence and for 1 week after the last dose of Calquence.

• Acalabrutinib